{"parse":{"title":"Lipinski's rule of five","pageid":826713,"revid":853935911,"text":{"*":"<div class=\"mw-parser-output\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">\"Rule of five\" redirects here. For the rule of thumb as it applies to the C++11 programming language, see <a href=\"/wiki/Rule_of_five_(C%2B%2B_programming)\" class=\"mw-redirect\" title=\"Rule of five (C++ programming)\">Rule of five (C++ programming)</a>.</div>\n<p><b>Lipinski's rule of five</b> also known as the <b>Pfizer's rule of five</b> or simply the <b>rule of five</b> (<b>RO5</b>) is a <a href=\"/wiki/Rule_of_thumb\" title=\"Rule of thumb\">rule of thumb</a> to evaluate <a href=\"/wiki/Druglikeness\" title=\"Druglikeness\">druglikeness</a> or determine if a <a href=\"/wiki/Chemical_compound\" title=\"Chemical compound\">chemical compound</a> with a certain <a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">pharmacological</a> or <a href=\"/wiki/Biological_activity\" title=\"Biological activity\">biological activity</a> has <a href=\"/wiki/Chemical_property\" title=\"Chemical property\">chemical properties</a> and <a href=\"/wiki/Physical_property\" title=\"Physical property\">physical properties</a> that would make it a likely <a href=\"/wiki/Bioavailability#In_pharmacology\" title=\"Bioavailability\">orally active</a> drug in humans. The rule was formulated by <a href=\"/wiki/Christopher_A._Lipinski\" title=\"Christopher A. Lipinski\">Christopher A. Lipinski</a> in 1997, based on the observation that most orally administered drugs are relatively small and moderately <a href=\"/wiki/Lipophilicity\" title=\"Lipophilicity\">lipophilic</a> <a href=\"/wiki/Molecule\" title=\"Molecule\">molecules</a>.<sup id=\"cite_ref-Lipinski_2001_1-0\" class=\"reference\"><a href=\"#cite_note-Lipinski_2001-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Lipinski_2004_2-0\" class=\"reference\"><a href=\"#cite_note-Lipinski_2004-2\">&#91;2&#93;</a></sup>\n</p><p>The rule describes <a href=\"/wiki/Molecular_property\" title=\"Molecular property\">molecular properties</a> important for a drug's <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a> in the human body, including their <a href=\"/wiki/Absorption_(pharmacokinetics)\" class=\"mw-redirect\" title=\"Absorption (pharmacokinetics)\">absorption</a>, <a href=\"/wiki/Distribution_(pharmacology)\" title=\"Distribution (pharmacology)\">distribution</a>, <a href=\"/wiki/Metabolism\" title=\"Metabolism\">metabolism</a>, and <a href=\"/wiki/Excretion\" title=\"Excretion\">excretion</a> (\"<a href=\"/wiki/ADME\" title=\"ADME\">ADME</a>\"). However, the rule does not predict if a compound is pharmacologically active.\n</p><p>The rule is important to keep in mind during <a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">drug discovery</a> when a pharmacologically active <a href=\"/wiki/Drug_discovery_hit_to_lead\" class=\"mw-redirect\" title=\"Drug discovery hit to lead\">lead structure</a> is optimized step-wise to increase the activity and selectivity of the compound as well as to ensure drug-like physicochemical properties are maintained as described by Lipinski's rule.<sup id=\"cite_ref-Oprea_2001_3-0\" class=\"reference\"><a href=\"#cite_note-Oprea_2001-3\">&#91;3&#93;</a></sup> Candidate drugs that conform to the RO5 tend to have lower attrition rates during <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a> and hence have an increased chance of reaching the market.<sup id=\"cite_ref-Lipinski_2004_2-1\" class=\"reference\"><a href=\"#cite_note-Lipinski_2004-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Leeson_2007_4-0\" class=\"reference\"><a href=\"#cite_note-Leeson_2007-4\">&#91;4&#93;</a></sup>\n</p>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Atorvastatin.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Atorvastatin.svg/220px-Atorvastatin.svg.png\" width=\"220\" height=\"113\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Atorvastatin.svg/330px-Atorvastatin.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Atorvastatin.svg/440px-Atorvastatin.svg.png 2x\" data-file-width=\"512\" data-file-height=\"264\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Atorvastatin.svg\" class=\"internal\" title=\"Enlarge\"></a></div><a href=\"/wiki/Lipitor\" class=\"mw-redirect\" title=\"Lipitor\">Lipitor</a> is a popular drug that conforms to Lipinski's rule of five.</div></div></div>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Components_of_the_rule\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Components of the rule</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Variants\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Variants</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Lead-like\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Lead-like</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#See_also\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#External_links\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Components_of_the_rule\">Components of the rule</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=1\" title=\"Edit section: Components of the rule\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Lipinski's rule states that, in general, an orally active drug has no more than one violation of the following criteria:\n</p>\n<ul><li>No more than 5 <a href=\"/wiki/Hydrogen_bond\" title=\"Hydrogen bond\">hydrogen bond</a> donors (the total number of <a href=\"/wiki/Nitrogen\" title=\"Nitrogen\">nitrogen</a>\u2013<a href=\"/wiki/Hydrogen\" title=\"Hydrogen\">hydrogen</a> and <a href=\"/wiki/Oxygen\" title=\"Oxygen\">oxygen</a>\u2013hydrogen <a href=\"/wiki/Chemical_bond\" title=\"Chemical bond\">bonds</a>)</li>\n<li>No more than 10 <a href=\"/wiki/Hydrogen_bond\" title=\"Hydrogen bond\">hydrogen bond</a> acceptors (all <a href=\"/wiki/Nitrogen\" title=\"Nitrogen\">nitrogen</a> or <a href=\"/wiki/Oxygen\" title=\"Oxygen\">oxygen</a> <a href=\"/wiki/Atoms\" class=\"mw-redirect\" title=\"Atoms\">atoms</a>)</li>\n<li>A <a href=\"/wiki/Molecular_mass\" title=\"Molecular mass\">molecular mass</a> less than 500 <a href=\"/wiki/Atomic_mass_unit\" class=\"mw-redirect\" title=\"Atomic mass unit\">daltons</a></li>\n<li>An octanol-water <a href=\"/wiki/Partition_coefficient\" title=\"Partition coefficient\">partition coefficient</a><sup id=\"cite_ref-Leo_5-0\" class=\"reference\"><a href=\"#cite_note-Leo-5\">&#91;5&#93;</a></sup> log <i>P</i> not greater than 5</li></ul>\n<p>Note that all numbers are multiples of five, which is the origin of the rule's name.\nAs with many other <a href=\"/wiki/Rules_of_thumb\" class=\"mw-redirect\" title=\"Rules of thumb\">rules of thumb</a>, (such as <a href=\"/wiki/Baldwin%27s_rules\" title=\"Baldwin&#39;s rules\">Baldwin's rules</a> for ring closure), there are many exceptions to Lipinski's Rule.\n</p>\n<h2><span class=\"mw-headline\" id=\"Variants\">Variants</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=2\" title=\"Edit section: Variants\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In an attempt to improve the predictions of <a href=\"/wiki/Druglikeness\" title=\"Druglikeness\">druglikeness</a>, the rules have spawned many extensions, for example the Ghose filter:<sup id=\"cite_ref-Ghose_1999_6-0\" class=\"reference\"><a href=\"#cite_note-Ghose_1999-6\">&#91;6&#93;</a></sup>\n</p>\n<ul><li><a href=\"/wiki/Partition_coefficient\" title=\"Partition coefficient\">Partition coefficient</a> log <i>P</i> in \u22120.4 to +5.6 range</li>\n<li><a href=\"/wiki/Molar_refractivity\" title=\"Molar refractivity\">Molar refractivity</a> from 40 to 130</li>\n<li>Molecular weight from 180 to 480</li>\n<li>Number of atoms from 20 to 70 (includes H-bond donors [e.g. OHs and NHs] and H-bond acceptors [e.g. Ns and Os])</li></ul>\n<p>Veber's Rule further questions a 500 molecular weight cutoff. The <a href=\"/wiki/Polar_surface_area\" title=\"Polar surface area\">polar surface area</a> and the number of rotatable bonds has been found to better discriminate between compounds that are orally active and those that are not for a large data set of compounds in the rat.<sup id=\"cite_ref-pmid12036371_7-0\" class=\"reference\"><a href=\"#cite_note-pmid12036371-7\">&#91;7&#93;</a></sup>   In particular, compounds which meet only the two criteria of:\n</p>\n<ul><li>10 or fewer rotatable bonds and</li>\n<li>Polar surface area no greater than 140 \u01fa<sup>2</sup></li></ul>\n<p>are predicted to have good oral bioavailability.<sup id=\"cite_ref-pmid12036371_7-1\" class=\"reference\"><a href=\"#cite_note-pmid12036371-7\">&#91;7&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Lead-like\">Lead-like</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=3\" title=\"Edit section: Lead-like\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>During drug discovery, lipophilicity and molecular weight are often increased in order to improve the affinity and selectivity of the drug candidate.  Hence it is often difficult to maintain drug-likeness (i.e., RO5 compliance) during hit and lead optimization.  Hence it has been proposed that members of <a href=\"/wiki/Chemical_library\" title=\"Chemical library\">screening libraries</a> from which hits are discovered should be biased toward lower molecular weight and lipophility so that medicinal chemists will have an easier time in delivering optimized drug development candidates that are also drug-like. Hence the rule of five has been extended to the <b>rule of three</b> (RO3) for defining <b>lead-like</b> compounds.<sup id=\"cite_ref-Congreve_2003_8-0\" class=\"reference\"><a href=\"#cite_note-Congreve_2003-8\">&#91;8&#93;</a></sup>\n</p><p>A rule of three compliant compound is defined as one that has:\n</p>\n<ul><li>octanol-water <a href=\"/wiki/Partition_coefficient\" title=\"Partition coefficient\">partition coefficient</a> log <i>P</i> not greater than 3</li>\n<li><a href=\"/wiki/Molecular_mass\" title=\"Molecular mass\">molecular mass</a> less than 300 <a href=\"/wiki/Atomic_mass_unit\" class=\"mw-redirect\" title=\"Atomic mass unit\">daltons</a></li>\n<li>not more than 3 <a href=\"/wiki/Hydrogen_bond\" title=\"Hydrogen bond\">hydrogen bond</a> donors</li>\n<li>not more than 3 <a href=\"/wiki/Hydrogen_bond\" title=\"Hydrogen bond\">hydrogen bond</a> acceptors</li>\n<li>not more than 3 rotatable bonds</li></ul>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=4\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Biopharmaceutics_Classification_System\" title=\"Biopharmaceutics Classification System\">Biopharmaceutics Classification System</a></li>\n<li><a href=\"/wiki/Chemical_structure\" title=\"Chemical structure\">Chemical structure</a></li>\n<li><a href=\"/wiki/Chemicalize.org\" class=\"mw-redirect\" title=\"Chemicalize.org\">Chemicalize.org</a>:<a href=\"/wiki/Chemicalize.org#List_of_the_predicted_structure_based_properties\" class=\"mw-redirect\" title=\"Chemicalize.org\">List of predicted structure based properties</a></li>\n<li><a href=\"/wiki/Fragment-based_lead_discovery\" title=\"Fragment-based lead discovery\">Fragment-based lead discovery</a></li>\n<li><a href=\"/wiki/QSAR\" class=\"mw-redirect\" title=\"QSAR\">QSAR</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=5\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Lipinski_2001-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Lipinski_2001_1-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (March 2001). \"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings\". <i>Adv. Drug Deliv. Rev</i>. <b>46</b> (1-3): 3\u201326. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0169-409X%2800%2900129-0\">10.1016/S0169-409X(00)00129-0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11259830\">11259830</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Adv.+Drug+Deliv.+Rev.&amp;rft.atitle=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&amp;rft.volume=46&amp;rft.issue=1-3&amp;rft.pages=3-26&amp;rft.date=2001-03&amp;rft_id=info%3Adoi%2F10.1016%2FS0169-409X%2800%2900129-0&amp;rft_id=info%3Apmid%2F11259830&amp;rft.aulast=Lipinski&amp;rft.aufirst=CA&amp;rft.au=Lombardo%2C+F&amp;rft.au=Dominy%2C+BW&amp;rft.au=Feeney%2C+PJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Lipinski_2004-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Lipinski_2004_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Lipinski_2004_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lipinski CA (December 2004). \"Lead- and drug-like compounds: the rule-of-five revolution\". <i>Drug Discovery Today: Technologies</i>. <b>1</b> (4): 337\u2013341. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.ddtec.2004.11.007\">10.1016/j.ddtec.2004.11.007</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Discovery+Today%3A+Technologies&amp;rft.atitle=Lead-+and+drug-like+compounds%3A+the+rule-of-five+revolution&amp;rft.volume=1&amp;rft.issue=4&amp;rft.pages=337-341&amp;rft.date=2004-12&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ddtec.2004.11.007&amp;rft.au=Lipinski+CA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Oprea_2001-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Oprea_2001_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Oprea TI, Davis AM, Teague SJ, Leeson PD (2001). \"Is there a difference between leads and drugs? A historical perspective\". <i>J Chem Inf Comput Sci</i>. <b>41</b> (5): 1308\u201315. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1021/ci010366a\">10.1021/ci010366a</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11604031\">11604031</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Chem+Inf+Comput+Sci&amp;rft.atitle=Is+there+a+difference+between+leads+and+drugs%3F+A+historical+perspective&amp;rft.volume=41&amp;rft.issue=5&amp;rft.pages=1308-15&amp;rft.date=2001&amp;rft_id=info%3Adoi%2F10.1021%2Fci010366a&amp;rft_id=info%3Apmid%2F11604031&amp;rft.aulast=Oprea&amp;rft.aufirst=TI&amp;rft.au=Davis%2C+AM&amp;rft.au=Teague%2C+SJ&amp;rft.au=Leeson%2C+PD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Leeson_2007-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Leeson_2007_4-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Leeson PD, Springthorpe B (November 2007). \"The influence of drug-like concepts on decision-making in medicinal chemistry\". <i>Nat Rev Drug Discov</i>. <b>6</b> (11): 881\u201390. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nrd2445\">10.1038/nrd2445</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17971784\">17971784</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Rev+Drug+Discov&amp;rft.atitle=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&amp;rft.volume=6&amp;rft.issue=11&amp;rft.pages=881-90&amp;rft.date=2007-11&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd2445&amp;rft_id=info%3Apmid%2F17971784&amp;rft.aulast=Leeson&amp;rft.aufirst=PD&amp;rft.au=Springthorpe%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Leo-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Leo_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Leo A, Hansch C, Elkins D (1971). \"Partition coefficients and their uses\". <i>Chem Rev</i>. <b>71</b> (6): 525\u2013616. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1021/cr60274a001\">10.1021/cr60274a001</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Chem+Rev&amp;rft.atitle=Partition+coefficients+and+their+uses&amp;rft.volume=71&amp;rft.issue=6&amp;rft.pages=525-616&amp;rft.date=1971&amp;rft_id=info%3Adoi%2F10.1021%2Fcr60274a001&amp;rft.aulast=Leo&amp;rft.aufirst=A&amp;rft.au=Hansch%2C+C&amp;rft.au=Elkins%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Ghose_1999-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Ghose_1999_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ghose AK, Viswanadhan VN, Wendoloski JJ (January 1999). \"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases\". <i>J Comb Chem</i>. <b>1</b> (1): 55\u201368. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1021/cc9800071\">10.1021/cc9800071</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10746014\">10746014</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Comb+Chem&amp;rft.atitle=A+knowledge-based+approach+in+designing+combinatorial+or+medicinal+chemistry+libraries+for+drug+discovery.+1.+A+qualitative+and+quantitative+characterization+of+known+drug+databases&amp;rft.volume=1&amp;rft.issue=1&amp;rft.pages=55-68&amp;rft.date=1999-01&amp;rft_id=info%3Adoi%2F10.1021%2Fcc9800071&amp;rft_id=info%3Apmid%2F10746014&amp;rft.aulast=Ghose&amp;rft.aufirst=AK&amp;rft.au=Viswanadhan%2C+VN&amp;rft.au=Wendoloski%2C+JJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid12036371-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid12036371_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid12036371_7-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (June 2002). \"Molecular properties that influence the oral bioavailability of drug candidates\". <i>J. Med. Chem</i>. <b>45</b> (12): 2615\u201323. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1021/jm020017n\">10.1021/jm020017n</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12036371\">12036371</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Med.+Chem.&amp;rft.atitle=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&amp;rft.volume=45&amp;rft.issue=12&amp;rft.pages=2615-23&amp;rft.date=2002-06&amp;rft_id=info%3Adoi%2F10.1021%2Fjm020017n&amp;rft_id=info%3Apmid%2F12036371&amp;rft.aulast=Veber&amp;rft.aufirst=DF&amp;rft.au=Johnson%2C+SR&amp;rft.au=Cheng%2C+HY&amp;rft.au=Smith%2C+BR&amp;rft.au=Ward%2C+KW&amp;rft.au=Kopple%2C+KD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Congreve_2003-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Congreve_2003_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Congreve M, Carr R, Murray C, Jhoti H (October 2003). \"A 'rule of three' for fragment-based lead discovery?\". <i>Drug Discov. Today</i>. <b>8</b> (19): 876\u20137. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S1359-6446%2803%2902831-9\">10.1016/S1359-6446(03)02831-9</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/14554012\">14554012</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Discov.+Today&amp;rft.atitle=A+%27rule+of+three%27+for+fragment-based+lead+discovery%3F&amp;rft.volume=8&amp;rft.issue=19&amp;rft.pages=876-7&amp;rft.date=2003-10&amp;rft_id=info%3Adoi%2F10.1016%2FS1359-6446%2803%2902831-9&amp;rft_id=info%3Apmid%2F14554012&amp;rft.aulast=Congreve&amp;rft.aufirst=M&amp;rft.au=Carr%2C+R&amp;rft.au=Murray%2C+C&amp;rft.au=Jhoti%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ALipinski%27s+rule+of+five\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Lipinski%27s_rule_of_five&amp;action=edit&amp;section=6\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.molinspiration.com/cgi-bin/properties\">Interactive Rule of Five calculator</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20070404073952/http://www.chemaxon.com/demosite/marvin/index.html\">Free online calculations of Hydrogen bond donor/acceptor, mass and logP</a> using <a href=\"/wiki/ChemAxon\" title=\"ChemAxon\">ChemAxon</a>'s Marvin and Calculator Plugins \u2013 requires Java</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.organic-chemistry.org/prog/peo/\">Calculation of Druglikeness</a> \u2013 requires Java</li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2194\nCached time: 20180920230107\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.136 seconds\nReal time usage: 0.165 seconds\nPreprocessor visited node count: 576/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 16762/2097152 bytes\nTemplate argument size: 447/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 11156/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.064/10.000 seconds\nLua memory usage: 2.6 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  135.513      1 -total\n 68.64%   93.014      1 Template:Reflist\n 51.67%   70.016      8 Template:Cite_journal\n 16.59%   22.486      1 Template:Redirect\n 10.18%   13.795      1 Template:Use_dmy_dates\n  7.05%    9.559      1 Template:DMCA\n  6.01%    8.150      1 Template:Dated_maintenance_category\n  4.10%    5.552      1 Template:FULLROOTPAGENAME\n  2.75%    3.731      1 Template:Ns_has_subpages\n  1.33%    1.807      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:826713-0!canonical and timestamp 20180920230106 and revision id 853935911\n -->\n</div>"},"langlinks":[{"lang":"ca","url":"https://ca.wikipedia.org/wiki/Regla_del_Cinc_de_Lipinski","langname":"Catalan","autonym":"catal\u00e0","*":"Regla del Cinc de Lipinski"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Rule_of_Five","langname":"German","autonym":"Deutsch","*":"Rule of Five"},{"lang":"es","url":"https://es.wikipedia.org/wiki/Regla_de_cinco_de_Lipinski","langname":"Spanish","autonym":"espa\u00f1ol","*":"Regla de cinco de Lipinski"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Regola_di_Lipinski","langname":"Italian","autonym":"italiano","*":"Regola di Lipinski"},{"lang":"he","url":"https://he.wikipedia.org/wiki/%D7%9B%D7%9C%D7%9C_%D7%94%D7%97%D7%9E%D7%99%D7%A9%D7%94_%D7%A9%D7%9C_%D7%9C%D7%99%D7%A4%D7%99%D7%A0%D7%A1%D7%A7%D7%99","langname":"Hebrew","autonym":"\u05e2\u05d1\u05e8\u05d9\u05ea","*":"\u05db\u05dc\u05dc \u05d4\u05d7\u05de\u05d9\u05e9\u05d4 \u05e9\u05dc \u05dc\u05d9\u05e4\u05d9\u05e0\u05e1\u05e7\u05d9"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E3%83%AA%E3%83%94%E3%83%B3%E3%82%B9%E3%82%AD%E3%83%BC%E3%81%AE%E6%B3%95%E5%89%87","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u30ea\u30d4\u30f3\u30b9\u30ad\u30fc\u306e\u6cd5\u5247"},{"lang":"sl","url":"https://sl.wikipedia.org/wiki/Pravilo_Lipinskega","langname":"Slovenian","autonym":"sloven\u0161\u010dina","*":"Pravilo Lipinskega"},{"lang":"sv","url":"https://sv.wikipedia.org/wiki/Lipinskis_fem-regel","langname":"Swedish","autonym":"svenska","*":"Lipinskis fem-regel"},{"lang":"uk","url":"https://uk.wikipedia.org/wiki/%D0%9F%D1%80%D0%B0%D0%B2%D0%B8%D0%BB%D0%BE_%D0%BF%27%D1%8F%D1%82%D0%B8","langname":"Ukrainian","autonym":"\u0443\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0430","*":"\u041f\u0440\u0430\u0432\u0438\u043b\u043e \u043f'\u044f\u0442\u0438"},{"lang":"zh","url":"https://zh.wikipedia.org/wiki/%E9%87%8C%E5%AE%BE%E6%96%AF%E5%9F%BA%E4%BA%94%E8%A7%84%E5%88%99","langname":"Chinese","autonym":"\u4e2d\u6587","*":"\u91cc\u5bbe\u65af\u57fa\u4e94\u89c4\u5219"}],"categories":[{"sortkey":"","hidden":"","*":"Use_dmy_dates_from_July_2012"},{"sortkey":"","*":"Medicinal_chemistry"},{"sortkey":"","*":"Pharmaceutical_industry"},{"sortkey":"","*":"Cheminformatics"},{"sortkey":"","*":"Drug_discovery"},{"sortkey":"","*":"Rules_of_thumb"}],"links":[{"ns":0,"exists":"","*":"Rule of five"},{"ns":0,"exists":"","*":"ADME"},{"ns":0,"exists":"","*":"Absorption (pharmacokinetics)"},{"ns":0,"exists":"","*":"Atomic mass unit"},{"ns":0,"exists":"","*":"Atoms"},{"ns":0,"exists":"","*":"Baldwin's rules"},{"ns":0,"exists":"","*":"Bioavailability"},{"ns":0,"exists":"","*":"Biological activity"},{"ns":0,"exists":"","*":"Biopharmaceutics Classification System"},{"ns":0,"exists":"","*":"ChemAxon"},{"ns":0,"exists":"","*":"Chemical bond"},{"ns":0,"exists":"","*":"Chemical compound"},{"ns":0,"exists":"","*":"Chemical library"},{"ns":0,"exists":"","*":"Chemical property"},{"ns":0,"exists":"","*":"Chemical structure"},{"ns":0,"exists":"","*":"Chemicalize.org"},{"ns":0,"exists":"","*":"Christopher A. Lipinski"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Distribution (pharmacology)"},{"ns":0,"exists":"","*":"Drug discovery"},{"ns":0,"exists":"","*":"Drug discovery hit to lead"},{"ns":0,"exists":"","*":"Druglikeness"},{"ns":0,"exists":"","*":"Excretion"},{"ns":0,"exists":"","*":"Fragment-based lead discovery"},{"ns":0,"exists":"","*":"Hydrogen"},{"ns":0,"exists":"","*":"Hydrogen bond"},{"ns":0,"exists":"","*":"Lipitor"},{"ns":0,"exists":"","*":"Lipophilicity"},{"ns":0,"exists":"","*":"Metabolism"},{"ns":0,"exists":"","*":"Molar refractivity"},{"ns":0,"exists":"","*":"Molecular mass"},{"ns":0,"exists":"","*":"Molecular property"},{"ns":0,"exists":"","*":"Molecule"},{"ns":0,"exists":"","*":"Nitrogen"},{"ns":0,"exists":"","*":"Oxygen"},{"ns":0,"exists":"","*":"Partition coefficient"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Physical property"},{"ns":0,"exists":"","*":"Polar surface area"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"QSAR"},{"ns":0,"exists":"","*":"Rule of five (C++ programming)"},{"ns":0,"exists":"","*":"Rule of thumb"},{"ns":0,"exists":"","*":"Rules of thumb"},{"ns":14,"exists":"","*":"Category:Use dmy dates from July 2012"}],"templates":[{"ns":10,"exists":"","*":"Template:Redirect"},{"ns":10,"exists":"","*":"Template:Use dmy dates"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Redirect hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Redirect"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":0,"exists":"","*":"Rule of five"}],"images":["Atorvastatin.svg"],"externallinks":["//doi.org/10.1016/S0169-409X(00)00129-0","//www.ncbi.nlm.nih.gov/pubmed/11259830","//doi.org/10.1016/j.ddtec.2004.11.007","//doi.org/10.1021/ci010366a","//www.ncbi.nlm.nih.gov/pubmed/11604031","//doi.org/10.1038/nrd2445","//www.ncbi.nlm.nih.gov/pubmed/17971784","//doi.org/10.1021/cr60274a001","//doi.org/10.1021/cc9800071","//www.ncbi.nlm.nih.gov/pubmed/10746014","//doi.org/10.1021/jm020017n","//www.ncbi.nlm.nih.gov/pubmed/12036371","//doi.org/10.1016/S1359-6446(03)02831-9","//www.ncbi.nlm.nih.gov/pubmed/14554012","http://www.molinspiration.com/cgi-bin/properties","https://web.archive.org/web/20070404073952/http://www.chemaxon.com/demosite/marvin/index.html","https://www.organic-chemistry.org/prog/peo/"],"sections":[{"toclevel":1,"level":"2","line":"Components of the rule","number":"1","index":"1","fromtitle":"Lipinski's_rule_of_five","byteoffset":1920,"anchor":"Components_of_the_rule"},{"toclevel":1,"level":"2","line":"Variants","number":"2","index":"2","fromtitle":"Lipinski's_rule_of_five","byteoffset":2676,"anchor":"Variants"},{"toclevel":1,"level":"2","line":"Lead-like","number":"3","index":"3","fromtitle":"Lipinski's_rule_of_five","byteoffset":3939,"anchor":"Lead-like"},{"toclevel":1,"level":"2","line":"See also","number":"4","index":"4","fromtitle":"Lipinski's_rule_of_five","byteoffset":4990,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"5","fromtitle":"Lipinski's_rule_of_five","byteoffset":5259,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"6","index":"6","fromtitle":"Lipinski's_rule_of_five","byteoffset":7578,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Lipinski's rule of five","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q916723"}]}}